- Home
- NBY vs IKT Comparison
NBY vs IKT Comparison
Compare NBY & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- IKT
- Stock Information
- Founded
- NBY 2000
- IKT 2008
- Country
- NBY United States
- IKT United States
- Employees
- NBY N/A
- IKT N/A
- Industry
- NBY
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- NBY
- IKT Health Care
- Exchange
- NBY Nasdaq
- IKT Nasdaq
- Market Cap
- NBY 3.3M
- IKT 159.2M
- IPO Year
- NBY 2007
- IKT 2020
- Fundamental
- Price
- NBY $0.53
- IKT $3.42
- Analyst Decision
- NBY Strong Buy
- IKT Strong Buy
- Analyst Count
- NBY 1
- IKT 2
- Target Price
- NBY $0.85
- IKT $6.50
- AVG Volume (30 Days)
- NBY 82.3K
- IKT 450.8K
- Earning Date
- NBY 11-07-2024
- IKT 11-14-2024
- Dividend Yield
- NBY N/A
- IKT N/A
- EPS Growth
- NBY N/A
- IKT N/A
- EPS
- NBY N/A
- IKT N/A
- Revenue
- NBY $13,844,000.00
- IKT $1.00
- Revenue This Year
- NBY N/A
- IKT N/A
- Revenue Next Year
- NBY $26.04
- IKT N/A
- P/E Ratio
- NBY N/A
- IKT N/A
- Revenue Growth
- NBY 15.40
- IKT N/A
- 52 Week Low
- NBY $0.36
- IKT $1.12
- 52 Week High
- NBY $9.10
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- NBY 39.55
- IKT 52.41
- Support Level
- NBY $0.49
- IKT $3.12
- Resistance Level
- NBY $0.58
- IKT $4.20
- Average True Range (ATR)
- NBY 0.03
- IKT 0.42
- MACD
- NBY -0.01
- IKT -0.00
- Stochastic Oscillator
- NBY 36.27
- IKT 30.67
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.